Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)